USE OF IL-1 INHIBITOR AND TNF ANTAGONIST PARTIALLY COMBINED WITH RECOMBINANT ERYTHROPOIETIN FOR ANAEMIA THERAPY

摘要

PPROBLEM TO BE SOLVED: To provide a pharmaceutical composition effective for therapy of blood disorder in mammals. PSOLUTION: The therapeutically effective amount of a pharmaceutical composition contains an interleukin 1 (IL-1) inhibitor and its use. Furthermore, a therapeutic method for blood disorder in mammals uses an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The present invention also relates to the IL-1 inhibitor composition, and a composition of the IL-1 inhibitor, the TNF inhibitor and the EPO receptor agonist. PCOPYRIGHT: (C)2009,JPO&INPIT